TrialReach, a London, UK-based online platform that connects patients with healthcare companies and research organizations to make new treatments available quickly and efficiently, raised £2m in funding.
The round was led by Octopus Investments, with participation from existing investors Amadeus Capital Partners, which led the funding raised by TrialReach in 2011 (read here).
The company intends to use the capital to develop products and launch new solutions that they have in the pipeline.
Founded in 2010 and led by Pablo Graiver, CEO, TrialReach has developed a platform that provides details of over 70,000 clinical trials that are currently authorized and regulated by health authorities. The company’s database gives patients access to the latest trials available, worldwide, to make informed choices and compare options. For research organisations, the platform can represent an innovative tool to reach patients efficiently and monitor enrolment, as well as real-time data to improve trial design.
FinSMEs
08/05/2013